Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38,527 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Auranofin Inhibition of Thioredoxin Reductase Sensitizes Lung Neuroendocrine Tumor Cells (NETs) and Small Cell Lung Cancer (SCLC) Cells to Sorafenib as well as Inhibiting SCLC Xenograft Growth.
Johnson SS, Liu D, Ewald JT, Robles-Planells C, Christensen KA, Bayanbold K, Wels BR, Solst SR, O'Dorisio MS, Allen BG, Menda Y, Spitz DR, Fath MA. Johnson SS, et al. Among authors: liu d. bioRxiv [Preprint]. 2024 Jan 30:2023.05.07.539772. doi: 10.1101/2023.05.07.539772. bioRxiv. 2024. Update in: Cancer Biol Ther. 2024 Dec 31;25(1):2382524. doi: 10.1080/15384047.2024.2382524 PMID: 37215042 Free PMC article. Updated. Preprint.
Pre-clinical Evaluation of Biomarkers for Early Detection of Nephrotoxicity Following Alpha-particle Radioligand Therapy.
Li M, Robles-Planells C, Liu D, Graves SA, Vasquez-Martinez G, Mayoral-Andrade G, Lee D, Rastogi P, Marks BM, Sagastume EA, Weiss RM, Linn-Peirano SC, Johnson FL, Schultz MK, Zepeda-Orozco D. Li M, et al. Among authors: liu d. bioRxiv [Preprint]. 2023 Sep 29:2023.09.27.559789. doi: 10.1101/2023.09.27.559789. bioRxiv. 2023. Update in: Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1395-1408. doi: 10.1007/s00259-023-06559-9 PMID: 37808634 Free PMC article. Updated. Preprint.
Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors.
Lee D, Li M, Liu D, Baumhover NJ, Sagastume EA, Marks BM, Rastogi P, Pigge FC, Menda Y, Johnson FL, Schultz MK. Lee D, et al. Among authors: liu d. Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):1147-1162. doi: 10.1007/s00259-023-06494-9. Epub 2023 Nov 13. Eur J Nucl Med Mol Imaging. 2024. PMID: 37955792 Free PMC article.
Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy.
Li M, Robles-Planells C, Liu D, Graves SA, Vasquez-Martinez G, Mayoral-Andrade G, Lee D, Rastogi P, Marks BM, Sagastume EA, Weiss RM, Linn-Peirano SC, Johnson FL, Schultz MK, Zepeda-Orozco D. Li M, et al. Among authors: liu d. Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1395-1408. doi: 10.1007/s00259-023-06559-9. Epub 2023 Dec 14. Eur J Nucl Med Mol Imaging. 2024. PMID: 38095674 Free PMC article.
Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC xenograft growth.
Johnson SS, Liu D, Ewald JT, Robles-Planells C, Pulliam C, Christensen KA, Bayanbold K, Wels BR, Solst SR, O'Dorisio MS, Menda Y, Spitz DR, Fath MA. Johnson SS, et al. Among authors: liu d. Cancer Biol Ther. 2024 Dec 31;25(1):2382524. doi: 10.1080/15384047.2024.2382524. Epub 2024 Jul 25. Cancer Biol Ther. 2024. PMID: 39054566 Free PMC article.
38,527 results
You have reached the last available page of results. Please see the User Guide for more information.